Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
PD-L1 expression in ccRCC associated with worse prognosis
Hong B et al. Clin Genitourin Cancer. 2018 Nov 13. doi: 10.1016/j.clgc.2018.11.001
Key clinical point: Expression of programmed death–ligand 1 (PD-L1) in both sporadic and hereditary clear cell renal cell carcinoma (ccRCC) was associated with worse prognosis.
Major finding: Median disease-free survival of patients with sporadic ccRCC tumors negative for PD-L1 was 36 months, compared with 28 months for patients with PD-L1-positive tumors.
Study details: A retrospective analysis of tissues from 129 patients with sporadic ccRCC and 26 with Von Hippel-Lindau–associated hereditary ccRCC.
Disclosures: The study was supported by the National Natural Science Foundation of China and Special Health Development Research Project of Capital. The authors reported having no relevant disclosures.
Hong B et al. Clin Genitourin Cancer. 2018 Nov 13. doi: 10.1016/j.clgc.2018.11.001.